Literature DB >> 19884659

The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells.

Li-Bing Song1, Jun Li, Wen-Ting Liao, Yan Feng, Chun-Ping Yu, Li-Juan Hu, Qing-Li Kong, Li-Hua Xu, Xing Zhang, Wan-Li Liu, Man-Zhi Li, Ling Zhang, Tie-Bang Kang, Li-Wu Fu, Wen-Lin Huang, Yun-Fei Xia, Sai Wah Tsao, Mengfeng Li, Vimla Band, Hamid Band, Qing-Hua Shi, Yi-Xin Zeng, Mu-Sheng Zeng.   

Abstract

The polycomb group protein B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) is dysregulated in various cancers, and its upregulation strongly correlates with an invasive phenotype and poor prognosis in patients with nasopharyngeal carcinomas. However, the underlying mechanism of Bmi-1-mediated invasiveness remains unknown. In the current study, we found that upregulation of Bmi-1 induced epithelial-mesenchymal transition (EMT) and enhanced the motility and invasiveness of human nasopharyngeal epithelial cells, whereas silencing endogenous Bmi-1 expression reversed EMT and reduced motility. Furthermore, upregulation of Bmi-1 led to the stabilization of Snail, a transcriptional repressor associated with EMT, via modulation of PI3K/Akt/GSK-3beta signaling. Chromatin immunoprecipitation assays revealed that Bmi-1 transcriptionally downregulated expression of the tumor suppressor PTEN in tumor cells through direct association with the PTEN locus. This in vitro analysis was consistent with the statistical inverse correlation detected between Bmi-1 and PTEN expression in a cohort of human nasopharyngeal carcinoma biopsies. Moreover, ablation of PTEN expression partially rescued the migratory/invasive phenotype of Bmi-1-silenced cells, indicating that PTEN might be a major mediator of Bmi-1-induced EMT. Our results provide functional and mechanistic links between the oncoprotein Bmi-1 and the tumor suppressor PTEN in the development and progression of cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19884659      PMCID: PMC2786794          DOI: 10.1172/JCI39374

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  78 in total

Review 1.  The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?

Authors:  William R Sellers; Massimo Loda
Journal:  Cancer Cell       Date:  2002-11       Impact factor: 31.743

Review 2.  Epithelial-mesenchymal transitions in tumour progression.

Authors:  Jean Paul Thiery
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

Review 3.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 4.  Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis.

Authors:  Stefan Grünert; Martin Jechlinger; Hartmut Beug
Journal:  Nat Rev Mol Cell Biol       Date:  2003-08       Impact factor: 94.444

5.  The polycomb group protein EZH2 is involved in progression of prostate cancer.

Authors:  Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan
Journal:  Nature       Date:  2002-10-10       Impact factor: 49.962

6.  Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells.

Authors:  In-kyung Park; Dalong Qian; Mark Kiel; Michael W Becker; Michael Pihalja; Irving L Weissman; Sean J Morrison; Michael F Clarke
Journal:  Nature       Date:  2003-04-20       Impact factor: 49.962

7.  Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells.

Authors:  Julie Lessard; Guy Sauvageau
Journal:  Nature       Date:  2003-04-20       Impact factor: 49.962

8.  Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator.

Authors:  Musheng Zeng; Ajay Kumar; Gaoyuan Meng; Qingshen Gao; Goberdhan Dimri; David Wazer; Hamid Band; Vimla Band
Journal:  J Biol Chem       Date:  2002-09-15       Impact factor: 5.157

9.  The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines.

Authors:  Sylvia Julien Grille; Alfonso Bellacosa; John Upson; Andres J Klein-Szanto; Frans van Roy; Whaseon Lee-Kwon; Mark Donowitz; Philip N Tsichlis; Lionel Larue
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

10.  Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains.

Authors:  Wolfgang Fischle; Yanming Wang; Steven A Jacobs; Youngchang Kim; C David Allis; Sepideh Khorasanizadeh
Journal:  Genes Dev       Date:  2003-08-01       Impact factor: 11.361

View more
  191 in total

1.  Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases--elevated Bmi-1 expression in late breast cancer relapses.

Authors:  Kristiina Joensuu; Jaana Hagström; Marjut Leidenius; Caj Haglund; Leif C Andersson; Hannu Sariola; Päivi Heikkilä
Journal:  Virchows Arch       Date:  2011-06-03       Impact factor: 4.064

Review 2.  The biology of head and neck cancer stem cells.

Authors:  Zhaocheng Zhang; Manoel Sant'Ana Filho; Jacques E Nör
Journal:  Oral Oncol       Date:  2011-11-08       Impact factor: 5.337

3.  Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway.

Authors:  T Palumbo; F R Faucz; M Azevedo; P Xekouki; D Iliopoulos; C A Stratakis
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

4.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 5.  Cancer stem cells: progress and challenges in lung cancer.

Authors:  Amanda K Templeton; Shinya Miyamoto; Anish Babu; Anupama Munshi; Rajagopal Ramesh
Journal:  Stem Cell Investig       Date:  2014-04-15

6.  miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.

Authors:  Shujing Liu; Michael T Tetzlaff; Tao Wang; Ruifeng Yang; Lin Xie; Gao Zhang; Clemens Krepler; Min Xiao; Marilda Beqiri; Wei Xu; Giorgos Karakousis; Lynn Schuchter; Ravi K Amaravadi; Weiting Xu; Zhi Wei; Meenhard Herlyn; Yuan Yao; Litao Zhang; Yingjie Wang; Lin Zhang; Xiaowei Xu
Journal:  Pigment Cell Melanoma Res       Date:  2015-05-16       Impact factor: 4.693

7.  Upregulation of C/EBPα contributes to colorectal cancer growth, metastasis and indicates poor survival outcome.

Authors:  Lan Mi; Kai Hu; Xianzi Wen; Jing Sun; Aiwen Wu; Mingliang Wang; Minhua Zheng; Lu Zang; Jiafu Ji
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

8.  ShRNA-mediated silencing of the ubiquitin-specific protease 22 gene restrained cell progression and affected the Akt pathway in nasopharyngeal carcinoma.

Authors:  Ya-Jing Zhuang; Zhi-Wei Liao; Hong-Wei Yu; Xian-Lu Song; Yuan Liu; Xing-Yuan Shi; Xiao-Dan Lin; Tong-Chong Zhou
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

9.  Bmi-1-shRNA inhibits the proliferation of lung adenocarcinoma cells by blocking the G1/S phase through decreasing cyclin D1 and increasing p21/p27 levels.

Authors:  Xiangyu Zheng; Yifang Wang; Ben Liu; Chunqing Liu; Dandan Liu; Jie Zhu; Chunhui Yang; Jiangzhou Yan; Xiaobo Liao; Xiuxiang Meng; Hong Yang
Journal:  Nucleic Acid Ther       Date:  2014-02-19       Impact factor: 5.486

10.  Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells.

Authors:  Yannick D Benoit; Mavee S Witherspoon; Kristian B Laursen; Amel Guezguez; Marco Beauséjour; Jean-Francois Beaulieu; Steven M Lipkin; Lorraine J Gudas
Journal:  Exp Cell Res       Date:  2013-04-12       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.